Modality
Small Molecule
MOA
CDK2i
Target
EGFR
Pathway
Epigenetic
UCPNHMyelofibrosis
Development Pipeline
Preclinical
~Feb 2024
→ ~May 2025
Phase 1
Aug 2025
→ Jul 2029
Phase 1Current
NCT05161882
651 pts·Myelofibrosis
2025-08→2029-07·Not yet recruiting
651 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-243.3y awayPh2 Data· Myelofibrosis
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Not yet…
Catalysts
Ph2 Data
2029-07-24 · 3.3y away
Myelofibrosis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05161882 | Phase 1/2 | Myelofibrosis | Not yet recr... | 651 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-2328 | Regeneron | Phase 1 | BCMA |